miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

MLA

de la Cruz-Ojeda, Patricia, et al. “MiR-200c-3p, MiR-222-5p, and MiR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.” Cells (2073-4409), vol. 11, no. 17, Sept. 2022, p. 2673. EBSCOhost, https://doi.org/10.3390/cells11172673.

APA

de la Cruz-Ojeda, P., Schmid, T., Boix, L., Moreno, M., Sapena, V., Praena-Fernández, J. M., Castell, F. J., Falcón-Pérez, J. M., Reig, M., Brüne, B., Gómez-Bravo, M. A., Giráldez, Á., Bruix, J., Ferrer, M. T., & Muntané, J. (2022). miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Cells (2073-4409), 11(17), 2673. https://doi.org/10.3390/cells11172673

Chicago

de la Cruz-Ojeda, Patricia, Tobias Schmid, Loreto Boix, Manuela Moreno, Víctor Sapena, Juan M. Praena-Fernández, Francisco J. Castell, et al. 2022. “MiR-200c-3p, MiR-222-5p, and MiR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.” Cells (2073-4409) 11 (17): 2673. doi:10.3390/cells11172673.